Home > Oncology > ASCO 2021 > Haematological Cancers > Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML

Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML

Presented By
Dr Stéphane de Botton , Institute Gustave Roussy, France
Conference
ASCO 2021
Trial
Phase 2, 2102M 101
First results of a phase 2 study demonstrated durable complete remissions in patients with relapsed/refractory IDH1 mutant acute myeloid leukaemia (AML) after monotherapy with IDH1 inhibitor olutasidenib. Isocitrate dehydrogenase 1 (IDH1) is a key enzyme in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1 mutations are causal in the development and/or progression of various types of cancer due to the supraphysiological production of D-2-hydroxyglutarate (2HG). IDH1 mutations occur in 6–10% of AML patients [1]. Olutasidenib is a highly potent selective and orally active inhibitor of IDH1 mutants, inhibiting 2HG over-production. The phase 2, multicohort 2102M 101 trial (NCT02719574) is evaluating olutasidenib as a single agent and in combination with azacitidine in IDH1 mutant AML patie...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on